Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2023-07-05 00:00:00 ET · period of report 2023-06-30 · accession 0000899243-23-017010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-07-05 | 2023-06-30 | VIR | SOFTBANK VISION FUND (AIV M1) L.P. | 10% | S - Sale | $25.11 | -700 | 16.68M | -0.0% | -$17.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-30 | S | D | 700 | $25.11 | 16,684,041 | I See footnote | — | — | (F2) SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. ("SVF"). SB Investment Advisers (UK) Limited ("SBIA UK") has been appointed as alternative investment fund manager ("AIFM") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments. |